World immunotherapy conference Oct.30, page-5

Rationale for combining eftilagimod alpha and pembrolizumabProblem: Low monocyte numbers at baseline leads to poor efficacy of anti-PD-1 therapySolution: efti(IMP321) increases monocyte numbers in cancer patients New Rationale for Combining efti (IMP321) with PD-1 Antagonists (pembrolizumab) 1.000.750.500.250.00Time (months)Overall SurvivalClassical monocytes > 19 % Classical monocytes < 19 %Source: Krieg et al., Nat. Med. 24, 2018. N=5 1 Monocytes are important for response and survival to pembrolizumab efti(IMP321) increases monocytes sustainably response to pembrolizumab more likely N=1 5 Source: AIPAC stage 1Classical Monocytes %17